{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:42:36Z","timestamp":1792662156824,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007419.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000}}],"reference-count":139,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007419.pub5","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:08:04Z","timestamp":1498090084000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis"],"prefix":"10.1002","author":[{"given":"Gianni","family":"Virgili","sequence":"first","affiliation":[{"name":"University of Florence; Department of Translational Surgery and Medicine, Eye Clinic; Largo Brambilla, 3 Florence Italy 50134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[{"name":"Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia-IRCCS; Ophthalmology; Via Livenza n 3 Rome Italy 00198"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R","family":"Evans","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine; Cochrane Eyes and Vision, ICEH; Keppel Street London UK WC1E 7HT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Gordon","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine; Cochrane Eyes and Vision, ICEH; Keppel Street London UK WC1E 7HT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[{"name":"University of Florence; Department of Neurosciences, Psychology, Drug Research and Children\u2019s Health; viale Gaetano Pieraccini, 6 Florence Italy 50139"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00417-007-0688-0","article-title":"Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial","volume":"246","author":"Ahmadieh","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Azad R Sain S Sharma YR Mahajan D Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study Oman Journal of Ophthalmology 2012 166 70","DOI":"10.4103\/0974-620X.106100"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","article-title":"A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3","volume":"130","author":"Rajendram","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"e72755","DOI":"10.1371\/journal.pone.0072755","article-title":"Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4)","volume":"8","author":"Sivaprasad","year":"2013","journal-title":"PloS ONE"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","article-title":"One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.ophtha.2011.02.018","article-title":"The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema","volume":"118","author":"Do","year":"2011","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub5-BIB0008|cit8","first-page":"1652","article-title":"Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001\/jamaophthalmol.2013.4592)","volume":"131","author":"Anonymous","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamaophthalmol.2013.4154","article-title":"Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial","volume":"131","author":"Bressler","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.ophtha.2012.01.049","article-title":"Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"119","author":"Dewan","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1064-77","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results","volume":"119","author":"Elman","year":"2012","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD007419.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1586\/17469899.2014.900439","article-title":"Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections","volume":"9","author":"Ekinci","year":"2014","journal-title":"Expert Review of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0018|cit18","first-page":"773","article-title":"Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema","volume":"118","author":"Ishibashi","year":"2014","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0019|cit19","unstructured":"NCT01100307 A phase 3 study to compare the efficacy and safety of 0.3 mg pegaptanib sodium to sham Injections In subjects with diabetic macular edema clinicaltrials.gov\/show\/NCT01100307"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0021|cit21","first-page":"115","article-title":"Efficacy and safety profile of ranibizumab versus laser photocoagulation in patients with diabetic macular edema. Re-Des Study","volume":"232","author":"Lopez-Galvez","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Comyn O Sivaprasad S Peto T Neveu MM Holder GE Xing W A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study) American Journal of Ophthalmology 2014 960 70","DOI":"10.1016\/j.ajo.2014.02.019"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1167\/iovs.11-7613","article-title":"Changes in vision and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham","volume":"52","author":"Loftus","year":"2011","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ophtha.2011.02.045","article-title":"A phase 2\/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema","volume":"118","author":"Sultan","year":"2011","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ajo.2013.04.026","article-title":"A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema","volume":"156","author":"Nepomuceno","year":"2013","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/2013.jamaophthalmol.91","article-title":"Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment","volume":"131","author":"Do","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0030|cit30","unstructured":"CRFB002DD13 A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period Novartis clinical trial results database www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/login.jsp"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0031|cit31","unstructured":"NCT01131585 A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period clinicaltrials.gov\/show\/NCT01131585"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0032|cit32","unstructured":"CRFB002D2201 A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement Novartis clinical trial results database www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/login.jsp"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study","volume":"33","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Berger A Sheidow T Li R Rehel B De Takacsy F Courseau AS A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis (\"RESPOND\") 16th Annual Canadian Diabetes Association\/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal 2013","DOI":"10.1016\/j.jcjd.2013.08.140"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0035|cit35","unstructured":"CRFB002DCA05 A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema Novartis clinical trial results database www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/login.jsp"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub5-BIB0036|cit36","first-page":"805","article-title":"Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8)","volume":"121","author":"Anonymous","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Lang GE Berta A Eldem BM Simader C Sharp D Holz FG Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study Ophthalmology 2013 2004 12","DOI":"10.1016\/j.ophtha.2013.02.019"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Mitchell P Annemans L Gallagher M Hasan R Thomas S Gairy K Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial British Journal of Opthalmology 2012 688 93","DOI":"10.1136\/bjophthalmol-2011-300726"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"615-62","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamaophthalmol.2013.4592","article-title":"Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial","volume":"131","author":"Mitchell","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","article-title":"Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD007419.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in asian patients with diabetic macular edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.ophtha.2014.07.008","article-title":"Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE","volume":"121","author":"Bressler","year":"2014","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0046|cit46","unstructured":"Mieler WF Kim JE Yau L Ehrlich JS Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago 2013"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/IAE.0b013e31822f55de","article-title":"Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema","volume":"32","author":"Soheilian","year":"2012","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0b013e31815ec261","article-title":"Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema","volume":"27","author":"Soheilian","year":"2007","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ophtha.2009.01.011","article-title":"Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema","volume":"116","author":"Soheilian","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jdiacomp.2015.03.009","article-title":"Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?","volume":"29","author":"Turkoglu","year":"2015","journal-title":"Journal of Diabetes and its Complications"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2015.11.021","article-title":"A crossover design for comparative efficacy: a 36-week randomized trial of bevacizumab and ranibizumab for diabetic macular edema","volume":"123","author":"Wiley","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD007419.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamaophthalmol.2013.143","article-title":"Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema","volume":"131","author":"Ahmadieh","year":"2013","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0054|cit54","unstructured":"CRFB002DFR08 Open-label, multicenter, study of the efficacy and safety of Lucentis\u00ae (ranibizumab 0.5 mg) in diabetic patients presenting a visual impairment due to diabetic macular edema in current medical practice (LUDIC) Novartis clinical trial results database. www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=9803"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0055|cit55","unstructured":"CRFB002DGB14 RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicentre, single-arm Phase IIIb study, with 12-month primary endpoint, assessing the efficacy and safety of Ranibizumab in patients with visual impairment Novartis clinical trial results database www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/products.jsp?divisionId=2&diseaseAreaID=12"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0056|cit56","unstructured":"CRFB002DNO02 An open-label, prospective, multicenter, uncontrolled, Proof of concept study assessing the efficacy of Lucentis (ranibizumab) administered by an individualized \u201ctreat and extend\u201d dosing regimen in patients with visual impairment due to dIabetic macular edema Novartis clinical trial results database. www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=10423"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema","volume":"114","author":"Scott","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/IAE.0b013e318217d739","article-title":"Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal\/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation","volume":"31","author":"Googe","year":"2011","journal-title":"Retina"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Diabetic Retinopathy Clinical Research Network Elman MJ Qin H Aiello LP Beck RW Bressler NM Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 2012 2312 8","DOI":"10.1016\/j.ophtha.2012.08.022"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/112067210801800614","article-title":"Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema","volume":"18","author":"Faghihi","year":"2008","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0061|cit61","unstructured":"NCT02985619 Bevacizumabe or triamcinolone for persistent diabetic macular edema (BEVATAAC) clinicaltrials.gov\/ct2\/show\/NCT02985619"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bjo.2007.129122","article-title":"Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)","volume":"92","author":"Paccola","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/IAE.0b013e3181e1ed07","article-title":"Intravitreal bevacizumab and\/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema","volume":"30","author":"Solaiman","year":"2010","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/bjophthalmol-2012-302451","article-title":"Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema","volume":"97","author":"Zehetner","year":"2013","journal-title":"British Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0065|cit65","first-page":"706","article-title":"Effect analysis of ranibizumab with laser photocoagulation therapy for diabetic macular edema","volume":"16","author":"Chen","year":"2016","journal-title":"International Eye Science"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/OPTH.S131381","article-title":"Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema","volume":"23","author":"Fouda","year":"2017","journal-title":"Clinical Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub5-BIB0067|cit67","first-page":"493","article-title":"Clinical study of grid pattern laser photocoagulation with ranibizumab for diabetic macular edema","volume":"16","author":"Huang","year":"2016","journal-title":"International Eye Science"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2298\/VSP140402074J","article-title":"Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema","volume":"72","author":"Jovanovi\u0107","year":"2015","journal-title":"Vojnosanitetski Pregled"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0069|cit69","unstructured":"NCT00387582 Efficacy study of lucentis in the treatment of diabetic macular edema - a phase II, single center, randomized study to evaluate the efficacy of ranibizumab versus focal laser treatment in subjects with diabetic macular edema clinicaltrials.gov\/show\/NCT00387582"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0070|cit70","unstructured":"NCT00997191 Intravitreal bevacizumab and intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema (IBeTA) clinicaltrials.gov\/show\/NCT00997191"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0071|cit71","unstructured":"NCT01445899 PF-04523655 dose escalation study, and evaluation of PF-04523655 with\/without ranibizumab in diabetic macular edema (DME) (MATISSE) clinicaltrials.gov\/ct2\/show\/study\/NCT01445899"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0072|cit72","unstructured":"NCT01565148 A randomized, multi-center, phase II study of the safety, tolerability, and bioactivity of repeated intravitreal injections of iCo-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in the treatment of diabetic macular edema (the iDEAL Study) (iDEAL) clinicaltrials.gov\/ct2\/show\/study\/NCT01565148"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0073|cit73","unstructured":"ChiCTR-TRC-12002417 A randomized controlled trial to compare the efficacy and safety of 1) macular laser vs. 2) repeated intravitreal bevacizumab vs. 3) combined repeated intravitreal bevacizumab with macular laser for diabetic macular edema www.chictr.org.cn\/hvshowproject.aspx?id=3319"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0074|cit74","unstructured":"NCT01635790 Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edema (BRDME) (BRDME) clinicaltrials.gov\/ct2\/show\/NCT01635790"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0075|cit75","unstructured":"NCT02194634 Safety and efficacy study of conbercept in diabetic macular edema (DME) (Sailing) clinicaltrials.gov\/ct2\/show\/NCT02194634"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0076|cit76","unstructured":"NCT02259088 A 12-month, randomized, efficacy and safety study of 0.5 mg ranibizumab vs laser in Chinese DME patients clinicaltrials.gov\/ct2\/show\/NCT02259088"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0077|cit77","unstructured":"NCT02348918 A phase 2 randomized, controlled, double-masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of Luminate\u00ae (ALG-1001) as compared to Avastin\u00ae and focal laser photocoagulation in the treatment of diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02348918"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0078|cit78","unstructured":"NCT02645734 The effect of bevacizumab and ziv-aflibercept in diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02645734"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0079|cit79","unstructured":"NCT02699450 A phase 2 study of RO6867461 in participants with center-involving diabetic macular edema (CI-DME) (BOULEVARD) clinicaltrials.gov\/ct2\/show\/NCT02699450"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0080|cit80","unstructured":"NCT02712008 Anti-vasculaR endothelial growth factor plUs anti-angiopoietin 2 in fixed comBination therapY: evaluation for the treatment of diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02712008"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMe058142","article-title":"Angiogenic pathways in diabetic retinopathy","volume":"353","author":"Aiello","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08820539909069541","article-title":"The pathogenesis of edema in diabetic maculopathy","volume":"14","author":"Antcliff","year":"1999","journal-title":"Seminars in Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/IAE.0b013e3182695b83","article-title":"Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months","volume":"33","author":"Arevalo","year":"2013","journal-title":"Retina"},{"issue":"6921","key":"10.1002\/14651858.CD007419.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration","volume":"308","author":"Anonymous","year":"1994","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11096-013-9779-7","article-title":"Bevacizumab versus ranibizumab: why are we not playing the joker?","volume":"35","author":"Banfi","year":"2013","journal-title":"International Journal of Clinical Pharmacy"},{"issue":"7","key":"10.1002\/14651858.CD007419.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jclinepi.2008.09.013","article-title":"The evidence provided by a single trial is less reliable than its statistical analysis suggests","volume":"62","author":"Borm","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.122.3.330","article-title":"Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography","volume":"122","author":"Brown","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ajo.2008.07.013","article-title":"Diabetic macular edema: what is focal and what is diffuse?","volume":"146","author":"Browning","year":"2008","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD007419.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Maguire","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/eye.2015.217","article-title":"Ranibizumab for the treatment of wet AMD: a summary of real-world studies","volume":"30","author":"Chong","year":"2016","journal-title":"Eye"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.icu.0000120711.35941.76","article-title":"Corticosteroids in posterior segment disease: an update on new delivery systems and new indications","volume":"15","author":"Ciulla","year":"2004","journal-title":"Current Opinions in Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0096|cit96","unstructured":"Deeks JJ Higgins JP Altman DG editor(s) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0099|cit99","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","author":"Schmidt-Erfurth","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"e5182","DOI":"10.1136\/bmj.e5182","article-title":"The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review","volume":"345","author":"Ford","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra021678","article-title":"Diabetic retinopathy","volume":"350","author":"Frank","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub5-BIB0102|cit102","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0103|cit103","unstructured":"GRADE Working Group, McMaster University GRADEpro GDT 2014"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub5-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005656.pub2","article-title":"Intravitreal steroids for macular edema in diabetes","author":"Grover","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Archives of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","article-title":"Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice","volume":"134","author":"Heier","year":"2016","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0108|cit108","unstructured":"Higgins JP Deeks JJ Altman DG editor(s) Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0109|cit109","unstructured":"Higgins JP Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"A324","DOI":"10.1016\/j.jval.2014.08.572","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"17","author":"Higgins","year":"2014","journal-title":"Value Health"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","article-title":"Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy","volume":"16","author":"Hussain","year":"2016","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"22","key":"10.1002\/14651858.CD007419.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2014.2536","article-title":"Revolution to a new standard treatment of diabetic macular edema","volume":"311","author":"Jampol","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"735","DOI":"10.18553\/jmcp.2015.21.9.735","article-title":"Treatment patterns of anti-vascular endothelial growth factor and laser therapy among patients with diabetic macular edema","volume":"21","author":"Jiang","year":"2015","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema","volume":"91","author":"Klein","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12886-015-0035-x","article-title":"Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)","volume":"15","author":"Korobelnik","year":"2015","journal-title":"BMC Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/archophthalmol.2010.44","article-title":"Intravitreous dexamethasone effects on different patterns of diabetic macular edema","volume":"128","author":"Kuppermann","year":"2010","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0117|cit117","unstructured":"Anti-vascular endothelial growth factor treatment for diabetic macular edema www.cms.gov\/medicare-coverage-database\/details\/technology-assessments-details.aspx?TAId=85&bc=AAAQAAAAAAAA&"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0118|cit118","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011230.pub2","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","author":"Moja","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"51","key":"10.1002\/14651858.CD007419.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17510","article-title":"Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study","volume":"17","author":"Olson","year":"2013","journal-title":"Health Technology Assessment"},{"issue":"13","key":"10.1002\/14651858.CD007419.pub5-BIB0120|cit120","first-page":"1","article-title":"Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis","volume":"9","author":"Medical Advisory Secretariat","year":"2009","journal-title":"Ontario Health Technology Assessment Series"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/eye.2015.214","article-title":"A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study)","volume":"29","author":"Ramu","year":"2015","journal-title":"Eye"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"Article ID 8571","DOI":"10.1155\/2014\/857148","article-title":"A 2-year, phase IV, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration in routine clinical practice: The EPICOHORT study","volume":"2014","author":"Pagliarini","year":"2014","journal-title":"Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajo.2016.09.002","article-title":"Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom national health service setting","volume":"172","author":"Patrao","year":"2016","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ophtha.2013.02.018","article-title":"Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema","volume":"120","author":"Callanan","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD007419.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"e102309","DOI":"10.1371\/journal.pone.0102309","article-title":"Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis","volume":"9","author":"Regnier","year":"2014","journal-title":"PloS ONE"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0126|cit126","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0129|cit129","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions.In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2016.05.023","article-title":"Counterfeit Avastin in India: Punish the criminals, not the patients","volume":"170","author":"Stewart","year":"2016","journal-title":"American Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0039-6257(04)00109-2","article-title":"Macular edema","volume":"49","author":"Tranos","year":"2004","journal-title":"Survey of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata Journal"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"e0159553","DOI":"10.1371\/journal.pone.0159553","article-title":"The efficacy and safety of current treatments in diabetic macular edema: a systematic review and network meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD007419.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12886-017-0401-y","article-title":"Demographics of patients receiving Intravitrealanti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials","volume":"17","author":"Ziemssen","year":"2017","journal-title":"BMC Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema","author":"Parravano","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub5-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub2","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema","author":"Parravano","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub5-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub3","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema","author":"Virgili","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub5-BIB0139|cit139","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub4","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","author":"Virgili","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007419.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD007419.pub5\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:10:09Z","timestamp":1628547009000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007419.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":139,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007419.pub5","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007419.pub6","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}